{
  "topic": {
    "stem": "AVACINCAPTAD_GA_AUTO_2",
    "name": "Avacincaptad pegol in GA (broader)",
    "ncts": [
      "NCT05839041",
      "NCT02686658",
      "NCT05536297",
      "NCT06659445",
      "NCT06779773",
      "NCT04435366",
      "NCT06970665"
    ],
    "drug_patterns": [
      "avacincaptad"
    ],
    "condition_patterns": [
      "geographic atrophy"
    ]
  },
  "trials": [
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": false,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT05839041",
        "aact_title": "A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)",
        "aact_acronym": "SIGLEC",
        "start_date": "2023-05-02",
        "primary_completion_date": "2026-04-30",
        "aact_intvs": [
          "avd-104",
          "avacincaptad"
        ],
        "aact_conditions": [
          "geographic atrophy of the macula",
          "macular degeneration"
        ],
        "pmid": null,
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Occurrence of Dose Limiting Toxicity in Part 1",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": true,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT02686658",
        "aact_title": "Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration",
        "aact_acronym": "",
        "start_date": "2015-12-15",
        "primary_completion_date": "2019-09-26",
        "aact_intvs": [
          "avacincaptad pegol",
          "sham"
        ],
        "aact_conditions": [
          "dry age-related macular degeneration",
          "geographic atrophy"
        ],
        "pmid": "32882310",
        "pubmed_year": 2021,
        "pubmed_doi": "10.1016/j.ophtha.2020.08.027",
        "aact_per_arm_counts": {
          "BG000": 26,
          "BG001": 25,
          "BG002": 26,
          "BG003": 42,
          "BG004": 83,
          "BG005": 84
        },
        "aact_primary_outcome_measure": "Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": false,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT05536297",
        "aact_title": "Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy",
        "aact_acronym": "",
        "start_date": "2022-09-26",
        "primary_completion_date": "2025-04-10",
        "aact_intvs": [
          "avacincaptad pegol"
        ],
        "aact_conditions": [
          "age-related macular degeneration",
          "geographic atrophy"
        ],
        "pmid": null,
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Number of participants with Adverse Events (AEs)",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": false,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT06659445",
        "aact_title": "Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD",
        "aact_acronym": "",
        "start_date": "2025-10-28",
        "primary_completion_date": "2028-11-30",
        "aact_intvs": [
          "onl1204 opthalmic solution",
          "avacincaptad pegol intravitreal solution",
          "sham"
        ],
        "aact_conditions": [
          "age - related macular degeneration (amd)",
          "geographic atrophy (ga)"
        ],
        "pmid": null,
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Primary Endpoint",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": false,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT06779773",
        "aact_title": "A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy",
        "aact_acronym": "",
        "start_date": "2025-01-22",
        "primary_completion_date": "2030-01-31",
        "aact_intvs": [
          "avacincaptad pegol (acp)"
        ],
        "aact_conditions": [
          "geographic atrophy",
          "macular degeneration"
        ],
        "pmid": null,
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Number of ACP injections",
        "aact_outcome_count_rows": []
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": true,
        "E_two_arms": true,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT04435366",
        "aact_title": "A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)",
        "aact_acronym": "",
        "start_date": "2020-06-22",
        "primary_completion_date": "2022-07-25",
        "aact_intvs": [
          "avacincaptad pegol",
          "sham"
        ],
        "aact_conditions": [
          "geographic atrophy",
          "macular degeneration"
        ],
        "pmid": "41407269",
        "pubmed_year": 2026,
        "pubmed_doi": "10.1016/j.ophtha.2025.12.011",
        "aact_per_arm_counts": {
          "BG000": 225,
          "BG001": 222
        },
        "aact_primary_outcome_measure": "The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12",
        "aact_outcome_count_rows": [
          [
            "OG000",
            "45.0"
          ],
          [
            "OG001",
            "35.0"
          ],
          [
            "OG000",
            "56.0"
          ],
          [
            "OG001",
            "43.0"
          ],
          [
            "OG000",
            "61.0"
          ],
          [
            "OG001",
            "49.0"
          ],
          [
            "OG000",
            "58.0"
          ],
          [
            "OG001",
            "65.0"
          ],
          [
            "OG000",
            "58.0"
          ],
          [
            "OG001",
            "58.0"
          ]
        ]
      }
    },
    {
      "gates": {
        "A_aact_exists": true,
        "B_drug_in_intvs": true,
        "C_condition_in_aact": true,
        "D_pmid_topic_match": false,
        "E_two_arms": false,
        "F_primary_outcome_known": true
      },
      "extracted": {
        "nct": "NCT06970665",
        "aact_title": "A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration",
        "aact_acronym": "",
        "start_date": "2025-07-08",
        "primary_completion_date": "2027-06-30",
        "aact_intvs": [
          "avacincaptad pegol"
        ],
        "aact_conditions": [
          "age-related macular degeneration",
          "geographic atrophy"
        ],
        "pmid": null,
        "aact_per_arm_counts": {},
        "aact_primary_outcome_measure": "Number of participants with Treatment Emergent Adverse Events (TEAEs)",
        "aact_outcome_count_rows": []
      }
    }
  ],
  "n_total": 7,
  "n_pass_all": 2,
  "verdict": "VIABLE",
  "pass_rate": 0.2857142857142857
}